Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091470 | 0.82 | SIGMAR1 (0.34) | SIGMAR1HTR1ATP53NISCHALDH1A1 | |
| SCHEMBL13091462 | 0.75 | SIGMAR1 (0.38) | SIGMAR1HTR1ATP53NISCHALDH1A1 | |
| SCHEMBL13091474 | 0.74 | FFAR2 (0.46) | SIGMAR1HTR1ATP53ALDH1A1THRB | |
| SCHEMBL13091467 | 0.73 | SIGMAR1 (0.36) | SIGMAR1HTR1ATP53OPRM1OPRL1 | |
| SCHEMBL13091472 | 0.72 | HTT (0.50) | SIGMAR1HTR1ATP53ALDH1A1THRB | |
| SCHEMBL833089 | 0.71 | NISCH (0.42) | SIGMAR1HTR1ATP53NISCH | |
| SCHEMBL28869631 | 0.68 | SIGMAR1 (0.46) | SIGMAR1HTR1ATP53NISCHOPRM1 | |
| SCHEMBL6554292 | 0.64 | SIGMAR1 (0.51) | SIGMAR1HTR1ATP53ALDH1A1HPGD | |
| SCHEMBL18733781 | 0.64 | DRD2 (0.38) | SIGMAR1HTR1ATP53DRD2DRD1 | |
| SCHEMBL15222074 | 0.64 | SMN1; SMN2 (0.41) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | SIGMAR1 3790/4885HTR1A 4293/4885TP53 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.